Cyclapolin 9

• Description :

  Cyclapolin 9 is a potent, selective and ATP-competitive polo-like kinase 1 (PLK1) inhibitor with an IC50 of 500 nM. Cyclapolin 9 is inactive against other kinases[1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H335

• Target :

  Polo-like Kinase (PLK)

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/cyclapolin-9.html

• Purity :

  98.09

• Solubility :

  DMSO : 20 mg/mL (ultrasonic; warming; heat to 80°C)

• Smiles :

  O=C(C1=[N+]([O-])C2=CC(C(F)(F)F)=CC([N+]([O-])=O)=C2S1)N

• Molecular Formula :

  C9H4F3N3O4S

• Molecular Weight :

  307.21

• Precautions :

  H315, H319, H335

• References & Citations :

  [1]Martin Hennenberg, et al. Inhibition of Prostate Smooth Muscle Contraction by Inhibitors of Polo-Like Kinases. Front Physiol. 2018 Jun 15;9:734.|[2]Campbell McInnes, et al. Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol. 2006 Nov;2 (11) :608-17.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PLK1

• CAS Number :

  [40533-25-3]